hours). [9] [10] [11] This limitation has prompted multiple efforts to extend the duration of the therapeutic effect, such as the placement of indwelling catheters and pumps for continuous delivery of bupivacaine. 12 Unfortunately, this approach can be cumbersome for the patient, is associated with risks of infection and dislodging, and increases costs. 13 DepoFoam bupivacaine (marketed as EXPAREL; Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) is a multivesicular liposome formulation of bupivacaine designed to allow diffusion of the drug over an extended period. The efficacy and safety of DepoFoam bupivacaine has been established across various surgical models, including bunionectomy, hemorrhoidectomy, total knee arthroplasty, and breast augmentation. [14] [15] [16] [17] Results from a Phase 2 study (data on file, Pacira Pharmaceuticals, Inc.) and a Phase 3 study, 17 both of which were multicenter, active-controlled, randomized, and double-blind, have shown that DepoFoam bupivacaine decreases postsurgical pain in women receiving breast implants. Additionally, in the Phase 3 study, DepoFoam bupivacaine reduced the requirement for postsurgical opioids.
Possible long-term safety complications associated with any use of saline and silicone gel implants include palpable but nonmalignant lumps, asymmetry, leaks, and ruptures. 18, 19 In particular, the US Food and Drug Administration has identified the rupture of breast implants as a primary safety concern. 20 While findings from the aforementioned studies characterize the safety profile of DepoFoam bupivacaine, properly addressing these concerns requires followup of more than 30 days. (Neither of the studies had initially carried out longer-term follow-up to determine the effects of treatment on the integrity of the implant.)
This observational multicenter two-year follow-up study was designed to evaluate safety outcomes in patients who had undergone breast augmentation and received DepoFoam bupivacaine, bupivacaine HCl, or both in the two prior studies. The primary objective was to assess clinical sequelae with respect to the integrity of the breast implants, as observed during a follow-up examination.
MEthOds
Study 1 was a Phase 2 active-controlled, randomized, double-blind study conducted at four clinical sites in the United States to evaluate the safety and efficacy of a single local administration of DepoFoam bupivacaine (133 mg or 266 mg) compared with bupivacaine HCl (75 mg; Marcaine, 0.5%, with epinephrine, 1:200,000; Hospira, Inc., Lake Forest, Illinois). The milligram dose of DepoFoam bupivacaine is expressed as the free base (ie, 266 mg of bupivacaine base is chemically equivalent to 300 mg of bupivacaine HCl). A total of 40 patients were randomized in a one-to-one ratio to receive (1) bupivacaine HCl (75 mg) in one breast implant pocket and DepoFoam bupivacaine (133 mg) in the other or (2) bupivacaine HCl (75 mg) in one breast implant pocket and DepoFoam bupivacaine (266 mg) in the other. Each patient served as her own control. The study drug was to be administered in the breast implant pockets via 18-gauge catheters, which were to be positioned during surgery and left in place until both sides were completed and sutured. At the end of surgery, the anesthetic solutions (DepoFoam bupivacaine in one side and bupivacaine HCl in the contralateral side, as assigned at randomization) were to be administered, and the catheters were to be subsequently withdrawn. The total volume to be administered was 20 mL in each implant pocket. Following surgery, patients received acetaminophen (1000 mg) three times daily and rescue analgesia with oxycodone as needed for breakthrough pain, through 96 hours after study drug administration.
Study 2 was a Phase 3 multicenter, parallel-group, active-controlled, randomized, double-blind study conducted at 11 clinical sites in the United States to evaluate the safety and efficacy of a single local administration of DepoFoam bupivacaine (266 mg) compared with bupivacaine HCl (100 mg; Marcaine, 0.5%, with epinephrine, 1:200,000; Hospira, Inc.) for postoperative analgesia. A total of 146 patients were randomized in a one-to-one ratio to receive a total of 532 mg of DepoFoam bupivacaine or 200 mg of bupivacaine HCl, divided equally into each breast pocket. Again, the study drug was administered in the right and left breast implant pockets by the surgeon's normal and usual technique and, if necessary, via standard catheters or feeding tubes from the surgical institution. After the study drug (DepoFoam bupivacaine or bupivacaine HCl, as assigned at randomization) was administered locally into both breast implant pockets, catheters/ tubes (if used) were flushed with a sufficient amount of saline to clear them of the study drug and then withdrawn. Gentle massage was applied to the area for about 30 seconds to ensure uniform distribution of the study drug inside the implant pocket. Patients received acetaminophen (1000 mg) three times daily and rescue analgesia with oxycodone as needed for breakthrough pain, through 96 hours after study drug administration.
Study procedures for both studies were conducted in accordance with the International Conference on Harmonisation's guidelines for good clinical practice and the Declaration of Helsinki and its amendments. 21, 22 Patients Participants in Studies 1 and 2 included women who were scheduled to undergo primary, bilateral, cosmetic, submuscular breast augmentation under general anesthesia. Patients from either study who were randomized and received the study drug were eligible for participation in this observational follow-up study. Patients were excluded if they had a clinically significant systemic or psychiatric disease that may have posed a significant safety risk or diminished their ability to undergo all study procedures and assessments. A total of 94 women (64%) from Studies 1 and 2 were enrolled in this follow-up evaluation, and all 94 completed the study and were evaluated; this included 78% of those eligible from Study 1 and 47% of those eligible from Study 2.
Study Design
Prior to enrolling patients into the current study, each site obtained approval from the appropriate Institutional Review Board.
Written informed consent was obtained from all patients at the screening visit (Day 0). Within 21 days, after providing informed consent, patients completed a questionnaire regarding their perception of how well they had healed since their augmentation mammaplasty. They also received a focused physical examination that assessed postsurgical healing and implant integrity. The survey included questions regarding breast pain, tenderness, tingling, numbness, burning, and changes in sensation, as well as relevant life events that may have had an impact on the implants (ie, chest wall surgery at the augmentation scar). The focused physical examination assessed potential sequelae of implant rupture or deflation, including decreased breast size, hard knots, uneven appearance of the breasts, and swelling. 23 The study ended when both the questionnaire and the physical examination were completed.
The safety measures selected for this study were based on signs and symptoms recognized by the US Food and Drug Administration as clinical manifestations of implant rupture 23 and were assessed by patient responses on the questionnaire and results of the physical examination. As this was an observational study with no interventions, adverse event data were not collected. Investigators and patients remained blinded to the treatments received during Studies 1 and 2.
Statistical Methods
Responses to the patient questionnaire and focused physical examination were summarized by treatment group, based on the study drug administered. No statistical tests were performed. For Study 1, the data summaries from the questionnaire and the physical examination were based on the affected breast. If both breasts were affected, then the data were summarized in both the bupivacaine HCl (75 mg) group and the appropriate DepoFoam bupivacaine group. If the affected breast was not reported, the response was attributed to both breasts/treatment groups.
The maximum sample size was the number of patients previously exposed to the study drug (DepoFoam bupivacaine or bupivacaine HCl) in Studies 1 and 2 (n = 176). Four centers (with a total of 27 patients) declined to participate, so the maximum number of patients potentially available for follow-up was 148.
REsuLts
In Study 1, statistically significant differences (P < .05) in the area under the curve for the Numeric Rating Scale score (0 = no pain, 10 = worst possible pain) at rest were observed in favor of DepoFoam bupivacaine compared with bupivacaine HCl through 72 hours, in addition to other time points. Additional statistically significant advantages for DepoFoam bupivacaine were demonstrated at multiple time points for the Numeric Rating Scale-Activity, Numeric Rating Scale-Rest, and area under the curve of the Numeric Rating Scale-Activity over the first 72 hours postsurgery. Mean scores were numerically lower with DepoFoam bupivacaine compared with bupivacaine HCl at most time points. DepoFoam bupivacaine was well tolerated; most reported adverse events were of mild or moderate intensity and were not considered to be related to study medication.
In
For this follow-up study, demographic and baseline characteristics were similar across the treatment groups (Table 1) . Overall, the mean age of the patients was 31.5 years (range, 20-54 years); 87% of patients were Caucasian; and the mean implant volume in the right and left breasts was 378.7 cc (range, 225-650 cc) and 377.6 cc (range, 175-650 cc), respectively. Only patients with an American Society of Anesthesiologists physical status classification of 1 or 2 were enrolled in the original studies. The mean number of months after treatment with DepoFoam bupivacaine or bupivacaine HCl that had elapsed before patients were enrolled in the follow-up study was 21 months (range, 19-24 months) for Study 1 and 15 months (range, 13-16 months) for Study 2.
Responses to the patient questionnaire are summarized in Table 2 . Most patients reported no breast pain, tenderness, tingling, numbness, burning, other changes in sensation, chest wall surgery or trauma, or other life events affecting the implant. Numbness was the most commonly reported sensation in both studies across all treatment groups, with a similar incidence reported in the DepoFoam bupivacaine and bupivacaine HCl groups. When reported, numbness was generally experienced during the first few months after study drug administration. Other changes in sensation in both studies included increased sensitivity (n = 5), decreased sensitivity (n = 7), vibration sensation (n = 1), nipple "still not as before" (n = 1), and unknown (n = 1). There was no clear indication that these changes were related to either treatment.
Abnormal physical examination findings are presented in Table 3 . The majority (> 90%) of patients across all treatment groups had no change in breast size, breast shape, skin, or nipple. There were no reports of palpable hard knots or swelling in patients from either study. In Study 1, at approximately 12 months, one patient (3.2%) reported an uneven appearance in the breast that received bupivacaine HCl (75 mg). Additionally, one patient reported signs of irritation or implant leakage in the breast that received bupivacaine HCl (75 mg). No uneven appearance of breasts or signs of irritation or implant leakage were reported for those treated with DepoFoam bupivacaine (133 mg or 266 mg). In Study 2, one patient who received bupivacaine HCl (100 mg) in each breast pocket had her right implant removed at the time of mastectomy for breast cancer, 15 months after she received the study drug. A safety committee reviewed the study data and determined that the malignancy was not related to the study drug.
disCussiOn
In this observational two-year follow-up study of patients who underwent submuscular breast augmentation mammaplasty, there was no observed indication of a negative impact of DepoFoam bupivacaine or bupivacaine HCl on the integrity of breast implants. Few patients reported changes in breast size, shape, skin, or nipple; no patients reported palpable hard knots or swelling. There was also no clear indication that administration of DepoFoam bupivacaine or bupivacaine HCl was associated with changes in breast sensation, including pain, tenderness, tingling, or numbness during the follow-up period.
To our knowledge, this is the first published report of results from an evaluation of the effects of local analgesics on the integrity of breast implants conducted after the acute postsurgical period. The findings from our study augment the safety findings observed in previous shortterm studies. In a retrospective chart review of 150 patients undergoing primary submuscular breast augmentation surgery in which 75 received 0.25% bupivacaine HCl with epinephrine during surgery, Jabs and colleagues reported no postoperative complications associated with bupivacaine. 24 In a study of 18 patients receiving breast implants treated with levobupivacaine in one breast and ropivacaine in the other, one patient had substantial edema in one breast treated with ropivacaine, which completely resolved within nine days after mastopexy. 25 Last, a comparison of bupivacaine HCl alone, ketorolac alone, or both agents instilled into the breast pocket before implant insertion showed no treatment-related complications. 7 None of these studies specifically assessed the effect of local analgesics on implant integrity past the acute postsurgical period.
Safety results from the current study are encouraging when considered in conjunction with physiocompatability data for DepoFoam bupivacaine and previously-reported data reflecting pharmacokinetic differences observed following administration of this novel formulation compared with conventional bupivacaine HCl. The physicochemical compatibility of DepoFoam bupivacaine with commonlyplaced smooth and textured silicone implants was examined in an ex vivo study (data on file, Pacira Pharmaceuticals, Inc.). In this study, the implants were submersed in either DepoFoam bupivacaine (15 mg/cc) or 0.9% saline at 37°C for seven days. The study results showed that the mechanical properties of the breast implants were not altered as a result of exposure to DepoFoam bupivacaine compared with saline. DepoFoam delivery technology allows for release of bupivacaine over an extended period, which results in a different pharmacokinetic profile following administration of DepoFoam bupivacaine compared with bupivacaine HCl. The pharmacokinetics of the two formulations have been evaluated in wound infiltration studies conducted in patients undergoing herniorrhaphy and total knee arthroplasty. 26 These studies showed that DepoFoam bupivacaine has a longer mean plasma half-life (12 to 19 hours) than that of bupivacaine HCl (nine to 11 hours). Also, administration of bupivacaine HCl resulted in a single peak in plasma bupivacaine concentration, while DepoFoam bupivacaine exhibited bimodal kinetics-an initial peak occurring within two hours, followed by a second occurring within 24 hours after administration. 26 Differences in efficacy between DepoFoam bupivacaine and bupivacaine HCl have also been reported. Bergese and colleagues 27 conducted an integrated analysis that focused on cumulative pain scores through 72 hours after study drug administration across 10 studies (N = 1459) that compared DepoFoam bupivacaine with bupivacaine HCl or placebo given via wound infiltration in five surgical models. Across these studies, 17 treatment arms compared DepoFoam bupivacaine with bupivacaine HCl. Betweengroup differences in cumulative pain intensity scores statistically significantly favored DepoFoam bupivacaine over bupivacaine HCl (P < .05) in five treatment arms and trended in favor of DepoFoam bupivacaine in nine treatment arms (only three comparisons trended in favor of bupivacaine HCl) without reaching statistically significant differences.
One of the strengths of this study is that patients and investigators remained blinded to the treatment that each patient received in Studies 1 and 2. The reasons for the differential in the proportion of patients from Study 1 (78%) and Study 2 (47%) who participated in the followup study are unclear; this information was not captured during the screening process for the follow-up study. Nevertheless, even a retention rate of 47% appears reasonable considering that two years had elapsed between the original intervention studies and the follow-up study. Limitations of the study include possible withdrawal bias (ie, the patients who declined to participate in the two-year follow-up study may have been substantially different from the patients who participated), as well as the subjectivity involved with patient-based questionnaires and the inherent limitations associated with an observational study design.
COnCLusiOns
In this two-year observational follow-up of patients who underwent submuscular breast augmentation mammaplasty, there was no meaningful difference in signs of postsurgical complications, such as changes in sensation or persistent pain, in patients who received either DepoFoam bupivacaine or bupivacaine HCl. Supportive of the literature and preclinical studies, the administration of DepoFoam bupivacaine for postoperative analgesia was not found to be associated with any safety concerns that would negatively affect the integrity of the breast implants, even up to two years after the procedure.
